Best Selling Vandetanib ZD6474 CAS 443913-73-3 High Quality Anti-Cancer Pharmaceutical Chemicals with Reasonable Prices

Superiority:

English name: Vandetanib

CAS number: 443913-73-3

Molecular formula: C22H24BrFN4O2

Molecular weight: 475.35

EINECS Number: 669-841-4

Melting point: 240-2430C

Boiling point: 538.2±50.0°C (Predicted)

Density: 1.406

Flash point: 279.3℃

Storage conditions: Keep in dark place, Inert atmosphere, Store in freezer, under-20°C

Vandetanib is a small molecule multi-target tyrosine kinase inhibitor developed by AstraZeneca. It was approved by the US FDA in April 2011 under the trade name of Zactima. This medicine is a tablet for the treatment of advanced medullary thyroid cancer in adult patients. Vandetanib is a multi-target tyrosine kinase inhibitor, belonging to the aniline quinazoline class of compounds, known as "second-generation Iressa", which not only acts on the EGFR, VEGFR and RET tyrosine kinases of tumor cells , but also inhibits other tyrosine kinases as well as serine/threonine kinases. Vandetanib is the first approved treatment for medullary thyroid cancer for the treatment of unresectable, locally advanced or metastatic symptomatic or progressive medullary thyroid cancer. Results of a randomized, placebo-controlled clinical trial showed that vandetanib significantly delayed the time to progression in locally advanced or metastatic medullary thyroid cancer. The recommended daily dose is 300 mg (oral), and treatment should be discontinued when the patient develops tolerance to the drug or cannot tolerate its toxicity. The most common adverse reactions to the drug were diarrhea, rash, acne, nausea, high blood pressure, headache, fatigue, decreased appetite, and abdominal pain. The incidence of adverse reactions is related to the dose. When <300mg/d, the patient tolerated it well, and the maximum tolerated dose (MTD) was 300mg. Phase II clinical studies involve many diseases. Clinical trials of vandetanib in the treatment of NSCLC are currently underway in my country. British AstraZeneca Pharmaceutical Co., Ltd. (AstraZeneca) obtained the world patent rights in May 2001 and October 2001 respectively (WO2001032651, WO2001074360), respectively, the structural formula of the compound, the synthesis method and the pharmaceutical composition (including the addition salt) ) and applied for corresponding protection. Vandetanib, which inhibits the development of medullary thyroid cancer, is the first FDA-approved drug to treat the disease and will help treat adult patients with advanced medullary thyroid cancer.

Q1.Are you a manufacturer or a trading company
A1.Our company is a leading manufacturer specializing in trade and the development, production and marketing of pharmaceutical intermediates and apis for more than 10 years.
Q2.What about the quality of your products
A2.We value quality as life.We strictly control the quality of each process, established a perfect quality control system.
Q3.In the third quarter.What is your minimum order quantity
A3.Our minimum order quantity is 1 gram.
Q4.Fourth quarter.Can you provide free test samples
A4.Yes, we can provide 10g free samples for consumer test.
Q5.What is your delivery time
A5.Delivery takes 2-3 days, depending on the destination.
Q6.What about the mode of transportation
A6.For urgent and light orders, UPS, FedEx, DHL, EMS can be used;For heavier goods, we provide the method of air or sea transportation to consumers.
Q7.So far.How about the terms of payment
A7.We accept T/T,  Paypal, , money gram, etc.